Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11487632 | 0.90 | CYP2D6 (0.49) | CYP2D6HSD11B1CCR2CYP3A4CYP2C19 | |
| SCHEMBL9330568 | 0.85 | AKR1C1 (0.47) | CYP2D6LMNA | |
| SCHEMBL4939280 | 0.84 | CCR2 (0.42) | HSD11B1CCR2MEN1KMT2A | |
| SCHEMBL4943758 | 0.82 | CCR2 (0.46) | CYP2D6HSD11B1CCR2CYP2C19 | |
| SCHEMBL9330906 | 0.80 | AKR1C1 (0.50) | CYP2D6LMNA | |
| SCHEMBL4942993 | 0.77 | HDAC4 (0.43) | — | |
| SCHEMBL11568427 | 0.77 | CCR2 (0.47) | CYP2D6HSD11B1CCR2CYP3A4CYP2C19 | |
| SCHEMBL12020309 | 0.74 | AKR1C1 (0.46) | CYP2D6LMNA | |
| SCHEMBL8105095 | 0.74 | AKR1C1 (0.46) | CYP2D6LMNA | |
| SCHEMBL8107068 | 0.74 | AKR1C1 (0.46) | CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103604-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | CYP2D6 1701/4885HSD11B1 161/4885CCR2 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.